ON CLINICAL MILESTONE - CYTOMED THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ITS FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ALLOGENEIC CAR-GAMMA DELTA T CELL THERAPY IN PATIENTS WITH ADVANCED SOLID TUM ...
Fort Lauderdale, FL, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ("Algorhythm”) (NASDAQ: RIME) - an AI-driven technology and consumer electronics holding company, announced today its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback